NL stock · Healthcare sector · Biotechnology
Company Logo

argenx SE

ARGXNASDAQ

380.90

USD
-1.20
(-0.31%)
Market Closed
-23.14P/E
-39Forward P/E
-1.16P/E to S&P500
21.100BMarket CAP
- -Div Yield
Upcoming Earnings
- -
Shares Short
1/13/23
777.89k
Short % of Float
- -
Short % of Shares Outs.
1.40%
% Held by Insiders
0.00%
% Held by Institutions
58.51%
Beta
0.51
PEG Ratio
-0.73
52w. high/low
407.93/256.44
Avg. Daily Volume
0.24M
Return %
Stock
S&P 500
1 year
49.64
(6.69)
3 years
163.25
24.50
5 years
410.86
42.35
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
69.26
17.33
111.43
55.50
167.64
96.15
312.06
103.75
382.15
248.21
407.93
249.50
404.90
365.90
Currency: USD
- -
- -
- -
- -
- -
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
- -
- -
- -
- -
- -
0.09
0.14
0.24
0.60
0.48
0.82
1.78
0.68
2.02
0.80
9.74
4.97
Earnings per share
- -
- -
- -
- -
- -
(0.29)
(0.82)
(0.54)
(1.66)
(1.06)
(1.19)
(1.37)
(2.12)
(4.73)
(11.65)
(7.99)
(17.19)
FCF per share
- -
- -
- -
- -
- -
(0.21)
(0.54)
(0.39)
(0.72)
(0.90)
0.52
(1.50)
(1.52)
2.40
(7.73)
(14.26)
(0.09)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
0.02
0.01
0.00
0.02
0.02
0.05
0.01
0.02
1.08
0.10
2.38
0.00
Book Value per sh.
- -
- -
- -
- -
- -
1.78
1.06
1.91
8.06
2.59
3.54
16.82
17.12
30.48
36.95
49.62
47.93
Comm.Shares outs.
- -
- -
- -
- -
- -
16
16
16
8
16
19
25
36
39
45
51
53
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(18.9)
(40.5)
(27.3)
(18.1)
(38.1)
(23.1)
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.8)
(1.6)
(1.1)
(0.5)
(1.3)
(1.2)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
1
2
4
5
7
15
44
25
78
36
497
263
Operating margin
- -
- -
- -
- -
- -
(323.6)%
(608.8)%
(232.7)%
(286.0)%
(227.7)%
(145.6)%
(63.0)%
(381.0)%
(255.9)%
(1,410.7)%
(70.1)%
(555.5)%
Depreciation (m)
- -
- -
- -
- -
- -
0
0
0
0
0
0
0
0
2
3
6
- -
Net profit (m)
- -
- -
- -
- -
- -
(4)
(13)
(8)
(13)
(17)
(22)
(34)
(76)
(183)
(529)
(408)
(909)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(2.2)%
(1.2)%
(3.0)%
(0.5)%
(2.1)%
2.6%
Net profit margin
- -
- -
- -
- -
- -
(308.0)%
(587.4)%
(229.0)%
(274.6)%
(223.4)%
(145.3)%
(77.1)%
(310.2)%
(233.5)%
(1,452.1)%
(82.1)%
(583.1)%
Working capital (m)
- -
- -
- -
- -
10
28
16
29
60
39
62
409
609
1,359
1,733
2,242
2,665
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5
6
8
6
Equity (m)
- -
- -
- -
- -
10
28
17
30
61
41
67
414
616
1,177
1,678
2,534
2,970
ROIC
- -
- -
- -
- -
- -
(16.1)%
(77.0)%
(28.2)%
(20.6)%
(41.1)%
(33.7)%
(8.1)%
(12.4)%
(12.8)%
(27.0)%
(16.0)%
(30.2)%
Return on capital
- -
- -
- -
- -
- -
(14.1)%
(55.9)%
(24.5)%
(17.6)%
(33.3)%
(20.2)%
(7.4)%
(11.4)%
(11.0)%
(23.0)%
(14.0)%
(28.5)%
Return on equity
- -
- -
- -
- -
- -
(16.1)%
(77.0)%
(28.2)%
(20.6)%
(41.1)%
(33.7)%
(8.1)%
(12.4)%
(15.5)%
(31.5)%
(16.1)%
(30.6)%
Plowback ratio
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
30 Jun · 2022 | Q2
All numbers in millions
Total liabilities
$ 279
Total assets
$ 3,249
Long-term debt
$ 6
Cash and equiv.
$ 1,367
Goodwill
$ - -
Retained earnings
$ (1,836)
Common stock
55
Enterprise Value
$ 19,739
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
1,496
2,001
2,337
Receivables
32
7
38
Inventory
- -
25
109
Other
10
877
1,023
Current assets
1,538
2,062
2,543
Acc. Payable
10
207
209
Debt due
2
3
4
Other
166
119
89
Current liabilities
179
329
301
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
1,265.21%
346.54%
203.55%
Cash flow
107.60%
(148.19)%
(124.22)%
Earnings
(22.81)%
108.18%
62.72%
Dividends
- -
- -
- -
Book value
51.02%
58.38%
107.56%
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
11
- -
- -
2021
158
312
1
26
497
2022
23
75
138
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
(3.47)
- -
- -
2021
(0.79)
2.03
(4.57)
(4.66)
(7.99)
2022
(4.36)
(4.01)
(4.26)
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Tim Van Hauwermeiren
Full-time employees:
650
City:
Breda
Address:
Willemstraat 5
IPO:
May 18, 2017
Website:
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.